Idenix Pharmaceuticals Inc  

(Public, NASDAQ:IDIX)   Watch this stock  
Find more results for IDIX
5.56
+0.03 (0.54%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.20 - 5.73
52 week 2.93 - 9.32
Open 5.57
Vol / Avg. 582,288.00/1.49M
Mkt cap 838.47M
P/E     -
Div/yield     -
EPS -0.91
Shares 150.80M
Beta 0.08
Inst. own 82%
Apr 28, 2014
Q1 2014 Idenix Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Apr 12, 2014
Idenix Pharmaceuticals, Inc. at European Association for the Study of the Liver (EASL): International Liver CongressT 2014
Apr 7, 2014
Idenix Pharmaceuticals, Inc. Promising Clinical Data Conference Call - Webcast
Mar 13, 2014
Idenix Pharmaceuticals, Inc. at Barclays Healthcare Conference
Mar 5, 2014
Idenix Pharmaceuticals, Inc. at Cowen Health Care Conference
Feb 27, 2014
Q4 2013 Idenix Pharmaceuticals, Inc. Earnings Release
Feb 13, 2014
Idenix Pharmaceuticals, Inc. at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -26073.99%
Operating margin - -26379.53%
EBITD margin - -25181.88%
Return on average assets -72.75% -62.41%
Return on average equity -94.41% -75.22%
Employees 107 -
CDP Score - -

Address

320 BENT STREET
CAMBRIDGE, MA 2141
United States - Map
+1-617-9959800 (Phone)
+1-617-9959801 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Officers and directors

Thomas R. Hodgson Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Ron C. Renaud Jr. President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Daniella Beckman Chief Financial Officer, Senior Vice President, Treasurer
Age: 34
Bio & Compensation  - Reuters
Jacques Dumas Ph.D. Executive Vice President, Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Douglas Mayers M.D. Executive Vice President - Clinical Development, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Maria D. Stahl Senior Vice President, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Paul J. Fanning Senior Vice President - Human Resources
Age: 55
Bio & Compensation  - Reuters
Charles A. Rowland Jr. Director
Age: 54
Bio & Compensation  - Reuters
Wayne T. Hockmeyer Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Tamar D. Howson Independent Director
Age: 65
Bio & Compensation  - Reuters